U.S., March 22 -- ClinicalTrials.gov registry received information related to the study (NCT06888102) titled 'A Platform Study of Epigenetic Therapy Before Prostatectomy in Men with Prostate Cancer' on Oct. 11, 2024.
Brief Summary: This is an open-label, non-randomized, exploratory platform protocol designed to assess the safety and antitumor activity of epigenetic therapies in participants with localized prostate cancer who are undergoing radical prostatectomy. The epigenetic therapy is intended to increase the sensitivity of the underlying tumor to the patient's immune system. The platform study will evaluate safety, biomarkers, and clinical activity of an epigenetic therapy. The particular details relevant to each module within this pla...